Intermediates
| Sr. No. | API Name | Intermediate Offered | CAS No. |
|---|---|---|---|
1 |
Acetazolamide |
2-Acetylamino-5-mercapto-1,3,4-thiadiazole | 32873-56-6 |
2 |
Alogliptin Benzoate |
2-[(6-Chloro-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl]benzonitrile | 865758-96-9 |
| (R)-tert-butyl (1-(3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl) piperidin-3-yl)carbamate | 1246610-74-1 | ||
3 |
Apixaban |
3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one | 545445-44-1 |
| Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1yl)phenyl)-4,5,6,7-tetrahydro-1H- pyrozolo[3,4-c] pyridine-3-carboxylate | 503614-91-3 | ||
4 |
Azilsartan Medoxomil Potassium |
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[(hydroxyamino)iminomethyl][1,1'- biphenyl]-4-yl]methyl]-,methyl ester | 147403-65-4 |
| 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'- biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester | 147403-52-9 | ||
| 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) [1,1'- biphenyl]-4-yl]methyl]-2-ethoxy- | 147403-03-0 | ||
5 |
Carvedilol |
4-(2,3-Epoxypropoxy)-carbazole or 9H-Carbazole,4-(2-oxiranylmethoxy)- | 51997-51-4 |
6 |
Celecoxib |
Sulfanilamide | 63-74-1 |
7 |
Chlorthalidone |
4-(4-chlorophenyl)-1H-benzo[d][1,2]oxazin-1-one | 2224-83-1 |
| 3-(4-chlorophenyl)isoindolin-1-one | 2224-77-3 | ||
| 2-chloro-5-(3-oxoisoindolin-1-yl)benzenesulfonamide | 82875-49-8 | ||
8 |
Dabigatran Etexilate Mesylate |
Ethyl 3-(2-((4-cyanophenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido) propanoate | 211915-84-3 |
| Ethyl 3-(2-((4-carbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido) propanoate | 429658-95-7 | ||
| Ethyl3-(2-((4-(N''-(hexyloxycarbonyl)carbamimidoyl) phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido) propanoate | 211915-06-9 | ||
9 |
Deferasirox |
2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one | 1218-69-5 |
10 |
Eslicarbazepine Acetate |
(±) -10,11-Dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide | 29331-92-8 |
| (S)-(+)-10,11-Dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide | 104746-04-5 | ||
11 |
Hydrochlorothiazide |
5-Chloroaniline-2,4-Disulfonamide | 121-30-2 |
12 |
Lamotrigine |
(2,3-Dichlorophenyl)-2-(guanidinylimino) acetonitrile or Lamotrigine Schiff Base | 84689-20-3 |
13 |
Linagliptin |
8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-Purine-2,6-dione | 666816-98-4 |
| 8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]- 1H-Purine-2,6-dione | 853029-57-9 | ||
14 |
Losartan Potassium |
2-Butyl-4-chloro-5-formylimidazole (BCFI) | 86857-96-9 |
15 |
Metoprolol Succinate |
2-((4-(2-Methoxyethyl)phenoxy)methyl)oxirane or Metoprolol Epoxide | 56718-70-8 |
| 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy) propan-2-ol or Metoprolol Base | 37350-58-6 | ||
16 |
Olmesartan Medoxomil |
(5-methyl-2-oxo-1,3-dioxol-4-yl) 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1′-biphenyl]-4-yl]methyl]- 1H-Imidazole-5-carboxylic acid (Trityl Olmesartan) | 144690-92-6 |
17 |
Rosuvastatin Calcium |
(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2 [(methanesulfonyl)methylamino]pyrimidin-5-yl]-3,5 dihydroxyhept -6-enoic acid tert-butyl ester or (Tert Butyl Rosuvastatin) | 355806-00-7 |
18 |
Saxagliptin |
(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide methane sulfonic acid | 709031-45-8 |
| N-[(1S)-2-[(1S,3S,5S)-3-Cyano-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo [3.3.1.1(3,7)]dec-1-yl)-2-oxoethyl]carbamic acid1,1-dimethylethyl esteror (BOC- Saxagliptin) | 709031-43-6 | ||
19 |
Sevelamer HCl |
Polyallyl amine hydrochloride [50% Aqueous Soln.] | 71550-12-4 |
20 |
Vildagliptin |
(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile | 207557-35-5 |
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.